Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals

Louis Velazquez

All NewsMay 7, 2025

Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ contract value.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent